Navigation Links
Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance
Date:11/10/2008

r 16.4%, from $28.3 million in the prior year quarter. Included in net interest expense in the quarter ended September 30, 2008 was $1.3 million relating to the write-off of deferred loan costs associated with the optional prepayment of $90.0 million of indebtedness under our senior secured credit facility, as compared to $1.1 million in the quarter ended September 30, 2007 as a result of the optional prepayment of $60.0 million of indebtedness under our senior secured credit facility. The decrease in net interest expense in the third quarter of 2008 period was primarily the result of cumulative reductions in outstanding debt during 2007 and 2008 which reduced the average debt balance outstanding from $1,355.0 million in the quarter ended September 30, 2007 to $1,126.1 million in the quarter ended September 30, 2008. The cumulative reduction in the average debt level is the result of optional prepayments made using cash flows from operations and cash on hand, net of investing activities.

Income taxes

Our effective tax rate for the quarter ended September 30, 2008 was 13.8%. The Company expects its annual effective tax rate for the year ended December 31, 2008 to approximate 17.0%. The effective tax rate for the quarter ended September 30, 2008 differs from the estimate of the full year 2008 due to the impact of discrete items.

Net Income and Cash Net Income

For the quarter ended September 30, 2008, reported net income was $40.1 million, or $0.16 per diluted share, and CNI was $96.5 million, or $0.39 per diluted share, based on 250.6 million diluted Class A common shares outstanding. In calculating CNI, we add back the after-tax impact of the amortization of intangible assets and the amortization and write-off of deferred financing costs. These items are tax-effected at the estimated marginal rates attributable to them. In the quarter ended September 30, 2008, the marginal tax rate associated with the amortization of intangible assets was
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2008 Financial Results
2. House Passes Historic Bill to Protect Kids From Tobacco; Senators Webb & Warner Should Cosponsor Legislation
3. Fitness and Figure Professionals Kirsten Nicewarner and Michelle Adams to Represent GNC at Vails Teva Mountain Games
4. The Oregon Clinic Extends Patient Care Services Across Metro Portland with Time Warner Telecoms Metro Ethernet Service
5. Warner Chilcott Announces Settlement of Securities Litigation
6. LodgeNet Appoints John E. Haire, Former Time Warner Executive, to Board of Directors
7. CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecoms IP VPN
8. Sharing Miracles Television Program to Feature Mountain Climber and Cancer Survivor Sean Swarner
9. Pinstripe Healthcare Group Adds Veteran HR Executive Warner as Client Services Director
10. Warner Chilcott Announces 2008 Financial Guidance
11. Warner Chilcott to Present at the 2008 Wachovia Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)...mpaign is a collaborative effort by the National A...PM), Midwives Alliance of North America (MANA), Ci...or Traditional Childbearing (ICTC), North American...ucation Accreditation Council (MEAC). To celebrat...ure federal recognition of CPMs language beneficia...
(Date:12/4/2009)...RNewswire/ -- Medithrive, Inc. has won the Patient...SF Bay Area by popular vote conducted by the onlin...months in operation, the SF Bay community has sele...essing medicinal marijuana. ,, The rapid rise...: a dispensary which caters to the consumer, provi...
(Date:12/4/2009)... Mich., Dec. 4 The Editorial Advis...sting Magazine today announced Allergan, Inc. (..." and C.R. Bard, Inc. (NYSE: BCR ) as its Febr...mational and educational use. ,, "The committee...volving its flagship drug Botox and other products...
(Date:12/4/2009)...dy shows that muscle cells grown in the lab can re...rly. The work, performed in dogs and rats, might u... as gastric reflux and fecal incontinence. , Thi...which are the bands of muscle that separate the ma... these areas can cause gastrointestinal esophageal...
(Date:12/4/2009)...ism is a phenomenon that was started by people tha...e of dental work in the US, Canada, and other coun...e, people have found that Mexican Dental Vacation ... , (PRWEB) December 4, 20...s, Mexican Dental Vacation is seeing their best ye...
Breaking Medicine News(10 mins):Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3
...linical trials of new drugs developed and would ma...argest potential of patients and diseases. Pharmac...l pharmaceutical companies would invest more than ...al Research and Department of Biotechnology have i...
...Affairs has approved to extend by five years the R...it over five million people.// The extension of...d involve an expenditure of Rs.11.56 billion ($255...t would be the treatment of 5.32 million TB patien...
...d people now a days need to be aware of the variou...xclusive information about //cosmetic surgery and ... The Department of Health says this website will ...ly many people opt for it. Hence there is a need t...
... intellect, according to McMaster University’s res...tudy which also said that there were differences b...shed in the journal Brain also said, said that in ...r right-handers only, indicating that brain asymme...
...s condition are more likely to smoke, and smoking ...asis results in inflammation and scaling of the sk...ack, elbows, knees, palms, face, and the soles of ...ology. Data from as many as 818 psoriasis p...
...at women with Alzheimer’s disease have low levels ...than women with a sound mental health. // The rese...s at the University of Chicago. Previous stu...a common characteristic of the disease. An...
Other Medicine News:Health News:Details of Cosmetic Surgery in a Special Website. 2Health News:Lack Of Estrogen In Brain Tissue Of Women Can Lead To Alzheimer's 2
(Date:12/4/2009)..., , DURHAM, N.C., Dec. 4 /PRNewswire-FirstCal...oard: OXBT) today announced that the first patient...se escalation, clinical trial in Switzerland for u...ry (TBI). Oxycyte is the Company,s perfluorocarbon...al is of invaluable importance in improving the ou...
(Date:12/4/2009)..., , ANNAPOLIS, Md., Dec. 4 /PRNewswire-Firs...biodefense company developing medical countermeasu...nced today the presentation of new data from the C...lyophilized recombinant Protective Antigen (rPA) b...tent after 16 months at various temperatures up to...
(Date:12/4/2009)..., , Opposes use of imported drugs often sto... Dec. 4 Today, the seni...efeat the Dorgan Importation plan encompassed in S..."Senator Dorgan,s importation amendment is poised ...g system to be breached, and our health to be enda...
Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgan's Drug Importation Plan Puts Seniors at Risk 2Free Compirion Bed Flow Webinar Helps Improve Patient Flow From ED to Inpatient Units 54747 1Free Compirion Bed Flow Webinar Helps Improve Patient Flow From ED to Inpatient Units 54747 2Free Compirion Bed Flow Webinar Helps Improve Patient Flow From ED to Inpatient Units 54747 3Thomson Reuters Joins the InChI Trust 13612 1Thomson Reuters Joins the InChI Trust 13612 27 Easy Tips for Healthy Aging 54745 17 Easy Tips for Healthy Aging 54745 2
...et, Inc. (Nasdaq:,MITI), a biopharmaceutical compa...e treatment of cancer, inflammation and autoimmune...1) showing cytotoxic activity of,anti-EpCAM antibo... colon,cancer cells on November 1, 2008 at the 23r...Biological Therapy of Cancer (iSBTc) , taking,plac...
...ionovo, Inc.,(Nasdaq: BNVI ) announced today that...BZL101, will advance to Phase 2 clinical testing a... clinical trial., The Phase 1B clinical trial was...of BZL101 and to determine the safety and feasibil...ment. A total of 27 women with,metastatic breast c...
Other Medicine Technology:Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells 2Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells 3Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells 4Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells 5Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer 2Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer 3Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer 4
J Cortex Extrator - Angled Right
J Cannula
J Hydrodissector - Newman
Side Cutting Cystotome
Medicine Products: